Background/Purpose: Streptococcus agalactiae (GBS), is the most common pathogen causing infections among perinatal women and neonatal babies. Nonetheless, there are few studies on the occurrence of GBS among the pregnant women and the mechanisms of GBS resistance to quinolones and macrolides in Taiwan. Methods: GBS were isolated from vaginas of the pregnant and non-pregnant symptomatic women in Taiwan. The prevalence, antimicrobial susceptibility, and mechanisms of resistance against erythromycin and quinolone of total 188 isolates were studied. Results: The isolation rate of GBS from pregnant women was significantly higher at 21.8% compare with the non-pregnant women of 13.2%. Antibiotic susceptibility test of the 188 GBS isolates revealed a high non-susceptible rate for erythromycin (50.0%) while the rate for levofloxacin was only 4.8%. Among 94 erythromycin non-susceptible GBS isolates, ermB gene was detected 83.1% (59/71) for those GBS that were non-susceptible to both clindamycin and tetracycline, which was significantly higher than GBS that are susceptible to clindamycin but resistant to tetracycline at 43.8% (7/16). No ermA or mef gene was detected in any isolate. Mutations were detected in the parC and gyrA genes in 14 out of 18 levofloxacin non-susceptible isolates. The predominant mutation type was the combination of Ser79Tyr in parC and Ser81Leu mutations in gyrA. Conclusion: GBS is the most common isolated pathogens in vaginal infections in Taiwan, resistance to tetracycline and erythromycin is higher than the rate observed for other regions of the world, while the resistance rate for levofloxacin was relatively lower in Taiwan.
Introduction
Streptococcus agalactiae, also known as group B streptococcus (GBS), usually resides in the human vagina and/or intestines. GBS is a predominant group of pathogens that causes perinatal infections. It has been proven that a high percentage of neonatal infections due to S. agalactiae (especially among newborns) occur through vertical transmission from a GBS-colonized mother to the newborn during labor and birth. Some 5e40% of women carry GBS in their genital tracts, and 10e30% of pregnant women have transient vaginal carriage.
1e3 GBS also causes bacteremia, endocarditis, skin and soft-tissue infections, and osteomyelitis among patients with compromised immune systems. 4e6 Therefore, maternal intrapartum prophylaxis for pregnant women colonized with GBS is recommended. While b-lactam antibiotics are the most commonly used antibiotics for treatment of GBS infection, the macrolide antibiotics are selected alternatives for patients with allergies to b-lactam agents or with less severe infections. Notably, GBS resistance to the macrolides and other antibiotics has increased gradually during the past several years. 7, 8 In addition, since the first report by Kawamura et al 9 in 2003 on quinolone-resistant GBS, these GBS isolates have also been identified in the United States, Spain, Brazil, and several other countries. Two principal mechanisms are involved in the resistance of GBS to erythromycin. One mechanism involves the methylation of the target gene, which is regulated by the erm gene, whereas the other is the efflux pump mediated by the mef gene. 5 Mutations of the gyrA and parC genes, which are located in the quinolone resistance-determining regions (QRDRs), are the main mechanisms for resistance to quinolones. 6,9,12e14 Nonetheless, there are only a few studies on the occurrence of GBS in pregnant women in Taiwan as well as on the mechanisms of GBS resistance to quinolones and macrolides in Taiwan. Therefore, we surveyed the pathogens isolated from pregnant women in Taiwan during a 1.5-year period to investigate the prevalence of GBS and antibiotic susceptibility and resistance of the isolated GBS strains. Moreover, for the erythromycinand quinolone-resistant GBS strains, we investigated the resistance mechanisms and associated genes in comparison with isolates from China.
Materials and methods

Sources of bacteria
Bacteria were isolated from vaginal swabs from 1088 patients during the period between January 1, 2011 and May 31, 2012 at the Kuo General Hospital in Tainan, Taiwan. The patients were 519 asymptomatic pregnant women with gestation period of 35e37 weeks and 569 nonpregnant but symptomatic women outpatients with vaginitis who were treated with drugs recommended by a clinician. Vaginal secretion was collected using the BBL CultureSwab Plus Collection and Transport Systems (Becton, Dickinson and Company, Sparks, MD, USA) following the manufacture's instruction. All isolates were identified using the Phoenix 100 fully automated bacterial identification and susceptibility testing system (Becton, Dickinson and Company). A total of 188 isolates were identified as S. agalactiae. The identities of these isolates were further confirmed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS; Bruker Biotyper, Bremen, German) analysis. The MALDI-TOF MS analysis produced significantly quick and reliable results and the species-level identification was 100%. 15, 16 Escherichia coli DH5a was used as a standard strain for the MALDI-TOF MS analysis.
To reveal and compare the resistance profiles and possible mechanisms of resistance from among those isolated at the Kuo General Hospital, 30 GBS isolates, including four erythromycin-susceptible isolates as controls and 26 erythromycin-nonsusceptible isolates, which had various kinds of minimum inhibitory concentration (MIC) levels (among them, 9 isolates were quinolone nonsusceptible), were selected for gene analysis. In addition, another 30 GBS isolates from the posterior vaginal fornix secretions of pregnant or healthy nonpregnant women, amniotic fluid of women in delivery, which had resistance profiles similar to those from the Kuo General Hospital were provided by the Second Affiliated Hospital of Zhejiang University, Hangzhou, China. All participants gave prior informed written consent to participate in the study.
Drug-susceptibility testing
Antibiotic susceptibility was determined using the Phoenix 100 system (Becton, Dickinson and Company) by the MIC method, and susceptibility judgment was based on the criteria set by the Clinical and Laboratory Standards Institute. 17 
Determination of efflux pump effects
An efflux mechanism was believed to be present when the MIC of an agent in the presence of reserpine was at least fourfold less (2 doubling dilutions) than the MIC in the absence of reserpine. 18 Efflux pump experiments were conducted with the modified broth dilution method of Bast et al 18 for the isolates that showed quinolone or erythromycin resistance but no mutations in QRDR (Isolates 1113, 1319, 1679, 2272) or in the ermA, ermB, and mefA genes (Isolates S8, S9, S11 from Zhejiang and Isolates 1113, 1319, 2272 from Taiwan). In brief, 100 mL of GBS strains at 1.5 Â 10 7 colony forming units/mL were inoculated in 2 mL of broth (with or without 10 mg/mL reserpine) containing different levels of levofloxacin. After incubation, the MICs of the strains were determined for levofloxacin or erythromycin resistance in the absence and presence of reserpine.
Polymerase chain reaction analysis
For the 24 isolates (9 nonsusceptible and 3 susceptible to levofloxacin from Taiwan and China, respectively) among the 60 GBS isolates used for comparison, polymerase chain reaction (PCR) of the relevant genes was conducted to detect mutations in parC, parE, gyrA, and gyrB for quinolone resistance. In this study, the gyrA and parC genes were amplified using the primers and conditions as described by Murayama et al, 6 whereas amplification of the gyrB and parE genes was conducted with modified primers based on the method suggested by Wehbeh et al. 12 For the 52 GBS isolates resistant to erythromycin, the ermA, ermB, and mefA genes were amplified using primers and conditions previously described. 19, 20 PCR amplification was performed using a TPersonal PCR cycler (Biometra, Göttingen, Germany).
DNA sequencing and analysis
The PCR products of the resistance genes were sequenced using an ABI 3730 sequencer (Applied Biosystems, Foster City, CA, USA), and the resulting sequences were compared with the relevant sequences of S. agalactiae GD201008-001 (accession number: CP003810.1) using DNAMAN software (Lynnon, Quebec, Canada).
Results
Isolation rate of GBS
Bacteria were isolated from 388 of the 1088 patients. Hemolytic reaction and biochemical identification indicated that 190 isolates were S. agalactiae. Among them, 114 isolates were from pregnant women and the remaining 76 were from nonpregnant women. Further confirmation testing using MALDI-TOF MS analysis showed that two of them (1 isolate each from the pregnant and nonpregnant groups) were actually Enterococcus faecalis. The isolation rate of GBS from pregnant women was 113/519 (21.8%) and that from nonpregnant women was 75/569 (13.2%). There was a significant difference between the two groups in GBS isolation rate by Chi-square test (p < 0.01). Overall, 188 (48.4%) isolates were identified to be GBS, forming the majority, followed by Candida albicans (95; 24.4%), E. coli (58; 15.0%), Klebsiella pneumoniae (9; 2.4%), and E. faecalis (7; 1.8%); in addition, another 31 species (8.0%) were also identified in this study.
Drug-sensitivity testing
We conducted antibiotic susceptibility testing on all 188 GBS isolates by determining the MICs of nine commonly used antibiotics including b-lactam, macrolide, quinolone agents, and vancomycin. As shown in Table 1 , the GBS strain showed the highest resistance to tetracycline (TE) with a nonsusceptibility rate close to 87%, followed by erythromycin and clindamycin (CC), which had nonsusceptibility rates of 50% and 41%, respectively, whereas only 4.8% of the 188 tested were nonsusceptible to levofloxacin. By contrast, the GBS isolates were highly susceptible to cefepime, chloramphenicol, meropenem, penicillin, and vancomycin. The vast majority of isolates (n Z 65, 34.6%) were identified as TE nonsusceptible but susceptible to all other antibiotics; the second type was nonsusceptible to TE, erythromycin, and CC but susceptible to all other antibiotics (n Z 48; 25.5%). However, 9.6% (n Z 18) of isolated strains were susceptible to all antibiotics. There was no significant difference between the pregnant and nonpregnant groups in GBS antibiotic susceptibility, except for erythromycin (Table 2) , as indicated by Chi-square test (p < 0.01).
Drug-sensitivity testing of quinolone-and macrolide-resistant GBS
To determine the resistance mechanisms and genes involved in quinolone and erythromycin resistance, we selected 30 isolates from the Kuo General Hospital, including nine levofloxacin-nonsusceptible isolates, which were also nonsusceptible to erythromycin. We also collected 30 GBS isolates from the Women's Healthcare Hospital (Jiaxing, China) and the Second Affiliated Hospital of Zhejiang University with similar resistance profiles. Further drug-susceptibility evaluations were conducted for nine clinically common antibiotics. The results are shown in Table 3 , which indicated that most of the isolates were highly susceptible to b-lactams. The susceptibility rates for the GBS isolates from both Taiwan and Zhejiang to penicillin were 100%, whereas the susceptibility rates to cefepime were 86.7% and 93.3%, respectively. Both the isolates from Taiwan and Zhejiang showed susceptibility rates of 13.3% and 70% to erythromycin and levofloxacin, respectively. Statistical analysis conducted using the Fisher's exact probability method indicated that there was no significant difference between the samples from the two regions in terms of the resistance profile. 
Detection and analysis of quinolone-resistance genes
No mutations were detected in the QRDRs for the parE and gyrB genes. The results of the mutation analysis for the parC and gyrA genes and levofloxacin resistance of the 24 GBS isolates tested (15 resistant, 3 intermediate, and 6 susceptible) are summarized in Table 4 . Sequences were deposited in the GenBank database and accession numbers for gyrA and parC were KF285457eKF285459. Among the 15 levofloxacinresistant and three intermediate isolates, one intermediate and 13 resistant isolates were detected to have mutations at either parC or gyrA. The majority of the isolates with mutations (10 of 14) displayed the same types of mutations, that is, Ser79Tyr and Ser81Leu. There were two isolates that had Ser79Phe and Ser81Leu mutations. In addition, there were two isolates that had an Ser79Tyr mutation in the parC gene or an Ser81Leu mutation in the gyrA gene. By contrast, no mutations were detected in the six levofloxacin-susceptible isolates. However, no mutations were detected from the four isolates (Isolates 1113, 1319, 1679, and 2272), which were phenotypically demonstrated to be either resistant or intermediate to levofloxacin.
Active efflux pump analysis
For the isolates that had quinolone nonsusceptibility but with no mutations on the QRDRs, the MICs of levofloxacin in the presence and absence of reserpine were determined. Similar experiments were also conducted for the six erythromycin-resistant isolates from which the ermA, ermB, and mefA genes were not identified. However, reserpine did not provide greater than a fourfold decrease in MIC for the tested isolates, indicating that the active pump mechanism was not functioning (data not shown).
Detection and analysis of erythromycin-resistant genes
From the 26 erythromycin-resistant GBS from Zhejiang, the ermB gene was detected in six (23.1%) isolates, whereas 14 of the 26 (53.8%) erythromycin-resistant GBS from Taiwan had the ermB gene (Table 5) . Neither the mefA nor ermA gene was detected in any of these investigated isolates. Because the 26 erythromycin-resistant GBS from Taiwan did not have either mefA or ermA, we further examined all Indicates that the data were analyzed using the Fisher's exact probability analysis, and use only a p but no c 2 . b Indicates that no statistical analysis was conducted. GBS Z group B streptococcus. remaining erythromycin-nonsusceptible GBS (68 strains) for mefA and ermA and obtained the same results. However, in the 94 erythromycin-nonsusceptible GBS strains obtained in this study, the ermB gene was detected in 69 isolates (73.4%), suggesting that the most predominant resistant mechanism may be due to the ermB gene product. For antibiotic patterns (1) erythromycin combined with CC and TE-resistant GBS, (2) CC susceptible but TE resistant, (3) CC resistant but TE susceptible, and (4) susceptible to both CC and TE, the ermB gene carried rate was 83.1% (59/71), 43.8% (7/16), 100% (3/3), and 0% (0/4), respectively (Table  5 ). There was a significant difference between the two groups [CC(R)/TE(R) vs. CC(S)/TE(R)] in terms of GBS nonsusceptibility to erythromycin and the ermB gene carried rate by Chi-square test (p < 0.01; Table 5 ). Although the rate of erythromycin nonsusceptibility for the GBS strains isolated from nonpregnant women was higher than the pregnant group (45/75 and 49/113, respectively), there was no difference in the occurrence of the ermB gene (33/45 and 36/49, respectively; p Z 0.99).
Discussion
GBS is the most common pathogen that causes infections in perinatal women and neonatal babies. In the United States and Europe, neonatal bacteremia, pneumonia, and meningitis due to GBS infections lead to a mortality rate as high as 4e6%. GBS also causes skin and soft-tissue infection, urinary bladder infection, bacteremia, pneumonia, endocarditis, and osteomyelitis in adults, especially in patients with diabetes and cancer. 4, 21 However, little attention has been paid to GBS infections in pregnant women in Taiwan.
We found that GBS accounted for almost half (48.4%) of the colonizing and clinical strains isolated from the vaginal tracts of women. This rate is much higher than that of C. albicans, which has been considered the commonest causative pathogen of vaginal infection. Our findings indicate the importance of monitoring GBS, especially in pregnant women.
GBS is reportedly highly resistant to erythromycin, TE, and CC. 7,22e24 We found that the nonsusceptibility rates for erythromycin, TE, and CC among the GBS isolates in Taiwan ranged from 41% to 87%. The resistance rate for TE was as high as 86.2%, which was almost as high as the reported rate (97.3%) in Tunisia, 22 slightly higher than the reported rate of 81.5% in China, 23 and much higher than the reported rate (46.5%) in Japan. 24 The nonsusceptibility rate for erythromycin was approximately 50%, which is close to the reported rate (50.7%) in the USA, 7 but greater than the rate reported in Tunisia (40.0%), 22 and less than the rate in China (71.2%), 23 indicating that the resistance of GBS to the macrolides in Taiwan is as critical as in the other regions of the world. By contrast, penicillin and cefepime showed high sensitivity, which is in accordance with other reports, 20, 22, 24 suggesting that penicillin is still among the best treatment choices for GBS infections.
PCR amplification and DNA sequencing of the 52 erythromycin-resistant GBS isolates (26 isolates each from Taiwan and China for comparison test) revealed that 20 (38.5%) carried the ermB gene (Table 5) , and the sequence was highly similar to that of GenBank Accession number EF422360.1, which was isolated from cattle in Taiwan. Neither mefA nor ermA was detected from the isolates. This finding is in line with the study by Betriu et al, 25 in showing that ermB is the main mechanism of erythromycin resistance in GBS. However, none of these three genes were detected in 20 of the 26 isolates from Zhejiang nor in 12 of the 26 isolates from Taiwan that were resistant to 
Leu Z leucine; Phe Z phenylalanine; Ser Z serine; Tyr Z tyrosine. In this study, 73.4% of the isolates carried the ermB gene of the total GBS erythromycin-nonsusceptible strains, and the rate is significantly higher than that reported in USA and Spain (13.0% and 58.1%, respectively) 4, 5 ; however, our rate is close to that reported in Japan (87%) by Murayama et al. 6 In addition, the ermA, ermB, or mefA genes were not detected in 26.6% of the isolates. Dogan et al 4 reported the types of GBS that were unable to detect any of the erythromycin-resistant determinants examined (ermA, ermB, and mefA), and were highly resistant to erythromycin but susceptible to CC. As indicated in Table 5 , in our comparison test, five isolates from Taiwan and China each showed results similar to that reported by Dogan et al 4 ; nevertheless, the ermB gene was detected in two strains. In the 94 erythromycin-nonsusceptible GBS isolates surveyed for ermA, ermB, and mefA, 69 had the ermB gene but not ermA and mefA. Among them, 16 isolates were erythromycin resistant but susceptible to CC and TE, seven carried the ermB gene, and nine did not (Table 5) . Although not currently reported in S. agalactiae, single-nucleotide changes in 23S ribosomal ribonucleic acid or in ribosomal proteins conferring macrolide resistance have been reported for many bacteria, including Streptococcus pneumoniae. 26, 27 It is thus possible that a ribosomal mutation is responsible for the resistance in this specific isolate. This result implies that there might be additional mechanisms that are involved with erythromycin resistance, which merits further investigation.
Only 4.8% of the total GBS isolates were levofloxacin nonsusceptible. This rate is significantly lower than that reported in China (37.7% resistance), 23 and is even lower than that reported in Japan (18.4% resistance), as reported by Ueno et al. 24 Quinolones are not normally used in China for treating GBS infections in pregnant women and newborns. However, because quinolones are widely used in China for both clinical and agricultural purposes as well as in animal feedings, continuous and wide use of quinolones could have elevated the resistance of various pathogens including GBS to the quinolones. Research 28 indicated that there is a high rate of bacteria in the environment that carries quinolone-resistant genes, which might be relevant to the high resistance to quinolones. In addition to plasmidmediated quinolone-resistant genes, there are other mechanisms such as the mutations in Subunits A and B of the DNA topoisomerases (gyrA, gyrB, parC, and parE ) that are also involved in the high resistance against quinolones. No mutations were detected in the QRDRs of the gyrB and parE genes, which is similar to reports of other studies indicating that mutations for quinolone resistance among the GBS isolates are mainly due to the mutations of the parC and gyrA genes. The main mutation pattern observed was Ser79Phe and Ser79Tyr in the parC gene and Ser81Leu in the gyrA gene. 6, 9, 12 There are a few reports in Taiwan and China for such data. In our current study, we detected mutations from 14 of the 18 levofloxacin-nonsusceptible isolates; the mutation patterns of Ser79Tyr in parC and Ser81Leu in gyrA were the most frequent, followed by Ser79Phe in parC and Ser81Leu in gyrA.
Although the resistance pattern of the 30 selected quinolone-and/or macrolide-resistant GBS from Taiwan had highly similar resistant profiles to those from China, the gene analysis indicated that the ermB-positive rate (53.8%, 14/26) for GBS from Taiwan was much higher than that of the isolates from China (23.1, 6/26). Among the 18 levofloxacin-nonsusceptible GBS isolates, nine were from Taiwan and nine were from China. Although the mutation patterns in the parC and gyrA genes from both Taiwan and China were dominated by the Ser79Tyr and Ser81Leu patterns, other mutations were also detected in the isolates from China: six isolates had the predominant Ser79Tyr and Ser81Leu mutations, one had Ser79Phe and Ser81Leu mutations, one had only the Ser79Tyr mutation, and one had only the Ser81Leu mutation. By contrast, only four of nine isolates in Taiwan had the Ser79Tyr and Ser81Leu mutations and one had the Ser79Phe and Ser81Leu mutations. No mutations were detected in the parC and gyrA genes from the four nonsusceptible isolates in Taiwan, which is similar to the results of Ki et al, 14 although these test strains were intermediate resistant to levofloxacin (Table 4) . Detection of the active efflux pump using reserpine as the inhibitor was unable to identify any isolates that demonstrated a greater than fourfold decrease in the MIC, indicating that the reserpine inhibiting efflux pump is not functioning in those isolates. Other mechanisms, including plasmid-encoded quinolone resistance, have been reported for Gram-negative organisms, 29 but their association with quinolone resistance in Gram-positive organisms has not been demonstrated. 30 Mutations outside the QRDRs may also contribute to the expression of resistance in streptococci. In a laboratorygenerated quinolone-resistant strain, mutations in the promoter region of the parE gene(s) decreased transcript levels of parC and increased ciprofloxacin resistance even when no mutations were present in the QRDR. 31 
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